A rare case of benign peritoneal strumosis was screened for driver mutations in genes relevant to currently approved cancer therapies. Therefore, three formalin fixed paraffin embedded issue sections were screened with the GeneReader Actionable Insights NGS panel (Qiagen, Hilden, Germany) for the occurrence of driver mutations. Several mutations were identified in drug-targetable genes, such as ALK, EGFR, and BRAF. The majority of identified mutations were single nucleotide variant, but also a insertion/ deletion mutation was identified. The presented dataset is the first NGS dataset available from a patient with benign peritoneal strumosis.
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Specifications Table

Subject area
Medicine, clinical and basic tumor research More specific subject area Benign peritoneal strumosis Type of data 
Value of the data
The knowledge on molecular alterations occurring in benign peritoneal strumosis is limited, the present data extent this limited knowledge.
The presented data could trigger further (multicenter) studies on benign strumosis. The data show that no benign peritoneal strumosis can occur without "classical" targetable mutations.
Data
A dataset obtained by next generation sequencing of drug-targetable genes of a clinical case with benign peritoneal strumosis is presented. Benign peritoneal strumosis is a clinical condition that is rarely observed [1] and so far was not characterized on a molecular level.
The dataset was obtained from histologically confirmed formalin fixed paraffin embedded tissue samples of a 33 year old Caucasian woman with benign peritoneal strumosis. To date there were no datasets available that reported the mutational landscape of drug-targetable genes in clinical cases of benign peritoneal strumosis.
We identified several mutations that to date are classified as mutations with uncertain pathogenic role ( Table 1 ). In particular, we observed the single nucleotide variation (SNV) c.4381A 4G (p.Ile1461Val) mutation in the ALK gene, the c.1822delC (p.His608fs) mutation in the BRAF gene, the c.1562G 4 A (p.Arg521Lys) mutation in the EGFR gene, the c.1963A 4G (p.Ile655Val) and the Table 1 Overview on the mutations detected by NGS in tissue samples of a patients with benign peritoneal strumosis.
Gene c. variant p.variant Type
His129Arg SNV Dataset of mutations identified in benign peritoneal strumosis analyzed by NGS.
c.3508C4 G (p.Pro1170Ala) mutation in the ERBB2 gene, the c.386A 4G (p.His129Arg) in the ERBB3 gene, as well as the c.291-10delT deletion in the KRAS gene.
Experimental design, materials, and methods
In order to identify putative therapy targets and to further characterize this rare clinical condition we have performed a Next Generation Sequencing (NGS) analyses using the GeneReader Actionable Insights panel (Qiagen, Hilden, Germany) as recently described [2, 3] . Briefly, DNA from three different FFPE tumor tissue samples from the patient was isolated with the Maxwell FFPE kit (Promega, Darmstadt, Germany) according to the manufacturer's protocol. The DNA samples were then processed for sequencing with the GeneRead QIAact Actionable Insights Tumor Panel strictly according to the manufacturer's recommendations as follows. The GeneRead QIAact Actionable Insights Tumor Panel was used for target enrichment of ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1. Following target enrichment, library preparation and clonal amplification was done using the GeneRead DNA Library Q Kit and the GeneRead Clonal Amp Q Kit. DNA quality and concentration was determined after target enrichment and library preparation with the QIAxcel DNA High Resolution Kit on the QIAxcel instrument. Sequencing was performed on the GeneReader instrument with the GeneRead Sequencing Q Kit. Qiagen Clinical Insight Software was used for analysis and interpretation of the results. Sequencing products are analyzed by comparison with the following reference sequences: NM_004304.4 (ALK), NM_004333.4 (BRAF), NM_005228.4 (EGFR), NM_004448.3 (ERBB2), NM_001982.3 (ERBB3), NM_001122742.1 (ESR1), NM_000222.2 (KIT), NM_004985.4 (KRAS), NM_002524.4 (NRAS), NM_006206.5 (PDGFRA), NM_006218.3 (PIK3CA), and NM_002880.3 (RAF1).
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